Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for Cardioprotection in Breast Cancer
NCT04023110Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carvedilol in Cardiotoxicity (2 arms), sponsored by Abramson Cancer Center. Primary endpoints: Left Ventricular Ejection Fraction at 24 months, Treatment Adherence at 12 months and 1 more. Started Aug 2019; status: completed.
02
Drugs
carvedilol
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT04023110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023110.